Ductal carcinoma in situ of the breast

Richard J. Lee, Laura A. Vallow, Sarah A. McLaughlin, Katherine S. Tzou, Stephanie L. Hines, Jennifer L. Peterson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ductal carcinoma in situ (DCIS) of the breast represents a complex, heterogeneous pathologic condition in which malignant epithelial cells are confined within the ducts of the breast without evidence of invasion. The increased use of screening mammography has led to a significant shift in the diagnosis of DCIS, accounting for approximately 27 of all newly diagnosed cases of breast cancer in 2011, with an overall increase in incidence. As the incidence of DCIS increases, the treatment options continue to evolve. Consistent pathologic evaluation is crucial in optimizing treatment recommendations. Surgical treatment options include breast-conserving surgery (BCS) and mastectomy. Postoperative radiation therapy in combination with breast-conserving surgery is considered the standard of care with demonstrated decrease in local recurrence with the addition of radiation therapy. The role of endocrine therapy is currently being evaluated. The optimization of diagnostic imaging, treatment with regard to pathological risk assessment, and the role of partial breast irradiation continue to evolve.

Original languageEnglish (US)
Article number123549
JournalInternational Journal of Surgical Oncology
Volume2012
DOIs
StatePublished - 2012

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Breast
Segmental Mastectomy
Radiotherapy
Therapeutics
Mastectomy
Incidence
Diagnostic Imaging
Mammography
Standard of Care
Epithelial Cells
Breast Neoplasms
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Lee, R. J., Vallow, L. A., McLaughlin, S. A., Tzou, K. S., Hines, S. L., & Peterson, J. L. (2012). Ductal carcinoma in situ of the breast. International Journal of Surgical Oncology, 2012, [123549]. https://doi.org/10.1155/2012/123549

Ductal carcinoma in situ of the breast. / Lee, Richard J.; Vallow, Laura A.; McLaughlin, Sarah A.; Tzou, Katherine S.; Hines, Stephanie L.; Peterson, Jennifer L.

In: International Journal of Surgical Oncology, Vol. 2012, 123549, 2012.

Research output: Contribution to journalArticle

Lee, RJ, Vallow, LA, McLaughlin, SA, Tzou, KS, Hines, SL & Peterson, JL 2012, 'Ductal carcinoma in situ of the breast', International Journal of Surgical Oncology, vol. 2012, 123549. https://doi.org/10.1155/2012/123549
Lee RJ, Vallow LA, McLaughlin SA, Tzou KS, Hines SL, Peterson JL. Ductal carcinoma in situ of the breast. International Journal of Surgical Oncology. 2012;2012. 123549. https://doi.org/10.1155/2012/123549
Lee, Richard J. ; Vallow, Laura A. ; McLaughlin, Sarah A. ; Tzou, Katherine S. ; Hines, Stephanie L. ; Peterson, Jennifer L. / Ductal carcinoma in situ of the breast. In: International Journal of Surgical Oncology. 2012 ; Vol. 2012.
@article{70187a6cc1334198955d089a04cacba5,
title = "Ductal carcinoma in situ of the breast",
abstract = "Ductal carcinoma in situ (DCIS) of the breast represents a complex, heterogeneous pathologic condition in which malignant epithelial cells are confined within the ducts of the breast without evidence of invasion. The increased use of screening mammography has led to a significant shift in the diagnosis of DCIS, accounting for approximately 27 of all newly diagnosed cases of breast cancer in 2011, with an overall increase in incidence. As the incidence of DCIS increases, the treatment options continue to evolve. Consistent pathologic evaluation is crucial in optimizing treatment recommendations. Surgical treatment options include breast-conserving surgery (BCS) and mastectomy. Postoperative radiation therapy in combination with breast-conserving surgery is considered the standard of care with demonstrated decrease in local recurrence with the addition of radiation therapy. The role of endocrine therapy is currently being evaluated. The optimization of diagnostic imaging, treatment with regard to pathological risk assessment, and the role of partial breast irradiation continue to evolve.",
author = "Lee, {Richard J.} and Vallow, {Laura A.} and McLaughlin, {Sarah A.} and Tzou, {Katherine S.} and Hines, {Stephanie L.} and Peterson, {Jennifer L.}",
year = "2012",
doi = "10.1155/2012/123549",
language = "English (US)",
volume = "2012",
journal = "International Journal of Surgical Oncology",
issn = "2090-1402",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Ductal carcinoma in situ of the breast

AU - Lee, Richard J.

AU - Vallow, Laura A.

AU - McLaughlin, Sarah A.

AU - Tzou, Katherine S.

AU - Hines, Stephanie L.

AU - Peterson, Jennifer L.

PY - 2012

Y1 - 2012

N2 - Ductal carcinoma in situ (DCIS) of the breast represents a complex, heterogeneous pathologic condition in which malignant epithelial cells are confined within the ducts of the breast without evidence of invasion. The increased use of screening mammography has led to a significant shift in the diagnosis of DCIS, accounting for approximately 27 of all newly diagnosed cases of breast cancer in 2011, with an overall increase in incidence. As the incidence of DCIS increases, the treatment options continue to evolve. Consistent pathologic evaluation is crucial in optimizing treatment recommendations. Surgical treatment options include breast-conserving surgery (BCS) and mastectomy. Postoperative radiation therapy in combination with breast-conserving surgery is considered the standard of care with demonstrated decrease in local recurrence with the addition of radiation therapy. The role of endocrine therapy is currently being evaluated. The optimization of diagnostic imaging, treatment with regard to pathological risk assessment, and the role of partial breast irradiation continue to evolve.

AB - Ductal carcinoma in situ (DCIS) of the breast represents a complex, heterogeneous pathologic condition in which malignant epithelial cells are confined within the ducts of the breast without evidence of invasion. The increased use of screening mammography has led to a significant shift in the diagnosis of DCIS, accounting for approximately 27 of all newly diagnosed cases of breast cancer in 2011, with an overall increase in incidence. As the incidence of DCIS increases, the treatment options continue to evolve. Consistent pathologic evaluation is crucial in optimizing treatment recommendations. Surgical treatment options include breast-conserving surgery (BCS) and mastectomy. Postoperative radiation therapy in combination with breast-conserving surgery is considered the standard of care with demonstrated decrease in local recurrence with the addition of radiation therapy. The role of endocrine therapy is currently being evaluated. The optimization of diagnostic imaging, treatment with regard to pathological risk assessment, and the role of partial breast irradiation continue to evolve.

UR - http://www.scopus.com/inward/record.url?scp=84866170687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866170687&partnerID=8YFLogxK

U2 - 10.1155/2012/123549

DO - 10.1155/2012/123549

M3 - Article

C2 - 22852075

AN - SCOPUS:84866170687

VL - 2012

JO - International Journal of Surgical Oncology

JF - International Journal of Surgical Oncology

SN - 2090-1402

M1 - 123549

ER -